RT Journal Article
SR Electronic
T1 Immunogenic Modulation of Cholangiocarcinoma Cells by Chemoimmunotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6353
OP 6361
VO 34
IS 11
A1 SHIGEO KOIDO
A1 SHIN KAN
A1 KOSAKU YOSHIDA
A1 SHINJI YOSHIZAKI
A1 KAZUKI TAKAKURA
A1 YOSHIHISA NAMIKI
A1 SHINTARO TSUKINAGA
A1 SHUNICHI ODAHARA
A1 MIKIO KAJIHARA
A1 MASATO OKAMOTO
A1 MASAKI ITO
A1 SEI-ICHI YUSA
A1 JIANLIN GONG
A1 HARUO SUGIYAMA
A1 TOSHIFUMI OHKUSA
A1 SADAMU HOMMA
A1 HISAO TAJIRI
YR 2014
UL http://ar.iiarjournals.org/content/34/11/6353.abstract
AB Background/Aim: Chemoimmunotherapy has been used to treat intrahepatic cholangiocarcinoma (ICC). However, little is known about the phenomena underlying the immunomodulation of ICC cells elicited by chemoimmunotherapy. Materials and Methods: Primary ICC cells from a patient with ICC who received gemcitabine followed by 5-fluorouracil (5-FU), both combined with dendritic cells pulsed with Wilms' tumor 1 (WT1) peptides were cultured. ICC cells were treated with gemcitabine, 5-FU or interferon (IFN)-γ in vitro. The phenotype of the ICC cells was examined by flow cytometry and quantitative reverse transcription polymerase chain reaction. Results: Stimulation of the ICC cells with gemcitabine resulted in up-regulation of WT1 mRNA, programmed death receptor ligand-1 (PDL1) and calreticulin. Gemcitabine, 5-FU and IFN-γ induced up-regulation of mucin-1. Moreover, human leukocyte antigen (HLA)-ABC, HLA-DR and PDL1 were extremely up-regulated by IFN-γ. Conclusion: Chemoimmunomodulating agents alter the immunogenicity of ICC cells, resulting in complex clinical efficacy results.